Q3 2019 13F Holders as of 30 Sep 2019
-
Type / Class
-
Debt / NOTE 0.625% 4/0
-
Number of holders
-
31
-
Total 13F principal, excl. options
-
353,229,426
-
Principal change
-
-19,865,486
-
Total reported value, excl. options
-
$328,455,222
-
Value change
-
-$20,999,650
-
Number of buys
-
12
-
Number of sells
-
-18
-
Price
-
$0.9293
Significant Holders of SUPERNUS PHARMACEUTICALS INC - NOTE 0.625% 4/0 as of Q3 2019
38 filings reported holding 868459AD0 - SUPERNUS PHARMACEUTICALS INC - NOTE 0.625% 4/0 as of Q3 2019.
SUPERNUS PHARMACEUTICALS INC - NOTE 0.625% 4/0 has 31 institutional bondholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of $353,229,426 of principal
.
Largest 10 bondholders include ADVENT CAPITAL MANAGEMENT /DE/ ($60,655,000 of principal), Allianz Asset Management GmbH ($50,980,000 of principal), JPMORGAN CHASE & CO ($44,814,000 of principal), NN Investment Partners Holdings N.V. ($38,700,000 of principal), PRUDENTIAL PLC ($38,553,000 of principal), MACKAY SHIELDS LLC ($22,455,000 of principal), CALAMOS ADVISORS LLC ($22,303,000 of principal), Invesco Ltd. ($14,627,000 of principal), STATE STREET CORP ($11,625,000 of principal), and SHENKMAN CAPITAL MANAGEMENT INC ($8,910,000 of principal).
This table shows the top 31 institutional bondholders of the company debt. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.